234 related articles for article (PubMed ID: 20072962)
1. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
[TBL] [Abstract][Full Text] [Related]
2. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
3. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
4. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
5. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
Renard E; Dubois-Laforgue D; Guerci B;
Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
[TBL] [Abstract][Full Text] [Related]
6. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
7. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
8. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
Kvapil M
Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
[TBL] [Abstract][Full Text] [Related]
9. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
[TBL] [Abstract][Full Text] [Related]
10. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
[TBL] [Abstract][Full Text] [Related]
12. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
[TBL] [Abstract][Full Text] [Related]
13. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
14. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
Meneghini LF; Dornhorst A; Sreenan S;
Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
[TBL] [Abstract][Full Text] [Related]
15. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
Raslova K
Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
[TBL] [Abstract][Full Text] [Related]
16. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
17. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
[TBL] [Abstract][Full Text] [Related]
18. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.
Pieber TR; Treichel HC; Hompesch B; Philotheou A; Mordhorst L; Gall MA; Robertson LI
Diabet Med; 2007 Jun; 24(6):635-42. PubMed ID: 17381500
[TBL] [Abstract][Full Text] [Related]
19. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
[TBL] [Abstract][Full Text] [Related]
20. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
Kabadi UM
Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
